Is Nabota available in the United States?

No, Nabota remains largely absent from U.S. medical aesthetics practices. It has achieved its scale primarily through strong market penetration in South Korea, Japan, Southeast Asia, and China rather than North American distribution.

How does Nabota compare to Botox and Dysport?

Nabota competes directly with Botox and Dysport in Asia-Pacific and emerging markets, but operates in a different geographic space than these brands. While Botox and Dysport dominate North America, Nabota has built a defensible regional position by establishing strong brand recognition in South Korea and Japan first, then expanding into Southeast Asia and China.

What does Nabota's 1 trillion won milestone mean for the global neuromodulator market?

The milestone demonstrates that non-Allergan and non-Galderma toxins can achieve substantial scale and profitability in international markets. It signals that the global neuromodulator market is increasingly fragmented, with regional players building strong positions outside North America rather than remaining dominated solely by Western brands.

Which countries drive Nabota's sales?

Nabota has achieved strong brand recognition and market penetration in South Korea, Japan, Southeast Asia, and China. These regions represent the core markets where Daewoong has built its customer base and achieved the 1 trillion won sales milestone.

Monday, August 24, 2026 Never miss a recall or a rule change Go Pro · $20/mo →

RegulatoryAbbVie Launches Phase 2 Forehead Lines Studytoday MarketFacial Rejuvenation Market Forecast to Hit $5.66B by 20302 days ago Business & M&AAllergan Aesthetics Overhauls Loyalty Programtoday Devices & TechXERF Technology Enters Australian Market for Skin Tightening2 days ago Business & M&AEvolus Expands Estyme to Canada, Australia, New Zealandtoday MarketArm Fat Now Top Body Sculpting Concern in Singapore2 days ago Devices & TechSofwave Hits One Million Treatments Milestonetoday RegulatoryCKD Bio Pursues China Botox Approval—2027 Launch Targeted2 days ago RegulatoryRevance Wins FDA Nod for Under-Eye Injectablesyesterday MarketGLP-1 Pill Era Is Forcing Beauty Market Shiftyesterday InjectablesAEON Releases Expanded ABP-450 Botox Biosimilar Datayesterday Devices & TechUltherapy PRIME Real-Time Imaging Reshapes Midface Liftingyesterday

Market

Daewoong's Nabota Crosses 1 Trillion Won in Cumulative Sales—Asian Toxin Gains Scale

Q: What is Nabota and how much has it sold?

Nabota is a botulinum toxin product made by South Korean pharmaceutical company Daewoong. It has surpassed 1 trillion Korean won (approximately $750 million USD) in cumulative lifetime sales, making it a major player in Asian and emerging markets.

South Korean neuromodulator reaches major sales milestone, signaling sustained demand outside North America.

By Evan at Inside MedSpa · Jul 26, 2026

1-YEAR MOVE

ABBV ▲11.6%

1-year price move by ticker
Ticker	Company	1-year change
ABBV	AbbVie (Allergan Aesthetics)	+11.6%

Daewoong Pharmaceutical announced that Nabota, its botulinum toxin product, has surpassed 1 trillion Korean won (approximately $750 million USD) in cumulative lifetime sales. The milestone underscores robust demand for Nabota across Asia-Pacific and emerging markets, where it competes alongside Botox, Dysport, and regional alternatives.

Inside MedSpa Pro

You've reached your free articles this week.

Keep reading every article, unlock the full trackers, and get the twice-a-week intelligence brief — from $20/mo, or $200/yr (two months free). Never miss a recall or a rule change.

Every article, unlocked — no weekly limit
The full 50-state law tracker, stock & M&A watch
The twice-a-week, 2-minute intelligence brief
Recalls, FDA clearances & safety signals as they hit

See everything you get →

Cancel anytime, one click · 14-day money-back on annual

https://insidemedspa.com/article/daewoong-nabota-1-trillion-won-cumulative-sales/

Discussion

Free alerts

Get flagged before it costs you.

We'll flag the moment a recall or rule change hits your practice. One email a week, one click to leave.

Free · weekly · unsubscribe anytime. Privacy.

This morning's brief · 6 AM

The free version stops here.

What today's moves mean for your margins — and exactly what to do — already went out to Pro. By the time the trade press explains it, the window to act has closed.

Go Pro · $20/mo Two minutes a morning. Cancel anytime.

Live · Market movers

STRATA Skin Sciences-50%Hims & Hers Health+6.03%Estée Lauder+6.02%Bausch Health (Solta)-5.43%The Beauty Health Company (HydraFacial)+3.65%

The full stock & M&A watch →

FDA Activity — Aesthetic Devices

Monthly 510(k) clearances vs. recalls.

510(k) clearances Recalls

FDA Activity — Aesthetic Devices — Monthly 510(k) clearances vs. recalls.
Month	510(k) clearances	Recalls
Jun '25	0	4
Jul '25	0	1
Sep '25	0	1
Oct '25	0	2
Jan '26	0	1
Feb '26	0	5
Mar '26	0	5
Apr '26	0	19
May '26	7	18
Jun '26	34	8
Jul '26	23	4
Aug '26	5	0

The 50-state regulation tracker →

Inside MedSpa Pro

By the time it's news, it's too late.

The rebate cut, the scope-of-practice bill, the competitor opening down the street — it hits your business before the trade press ever covers it. Pro gets you there first: what happened, why it touches your margins, and exactly what to do — at 6 AM, in two minutes.

Go Pro · $20/mo Never miss a recall or a rule change. Cancel anytime.

The twice-a-week intelligence brief Go Pro · $20/mo →

Daewoong's Nabota Crosses 1 Trillion Won in Cumulative Sales—Asian Toxin Gains Scale

Share

Discussion

Leave a comment

By the time it's news, it's too late.